S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The 3-Stock Retirement Blueprint (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Moldova signs new energy deal that could ease blackout risk
The 3-Stock Retirement Blueprint (Ad)
OPEC+ oil producers face uncertainty over Russian sanctions
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
Why Your IRA Could Crash on January 16th? (Ad)
OPEC keeps oil targets amid uncertainty on Russian sanctions
FDA change ushers in cheaper, easier-to-get hearing aids
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The 3-Stock Retirement Blueprint (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Moldova signs new energy deal that could ease blackout risk
The 3-Stock Retirement Blueprint (Ad)
OPEC+ oil producers face uncertainty over Russian sanctions
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
Why Your IRA Could Crash on January 16th? (Ad)
OPEC keeps oil targets amid uncertainty on Russian sanctions
FDA change ushers in cheaper, easier-to-get hearing aids
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The 3-Stock Retirement Blueprint (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Moldova signs new energy deal that could ease blackout risk
The 3-Stock Retirement Blueprint (Ad)
OPEC+ oil producers face uncertainty over Russian sanctions
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
Why Your IRA Could Crash on January 16th? (Ad)
OPEC keeps oil targets amid uncertainty on Russian sanctions
FDA change ushers in cheaper, easier-to-get hearing aids
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The 3-Stock Retirement Blueprint (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Moldova signs new energy deal that could ease blackout risk
The 3-Stock Retirement Blueprint (Ad)
OPEC+ oil producers face uncertainty over Russian sanctions
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
Why Your IRA Could Crash on January 16th? (Ad)
OPEC keeps oil targets amid uncertainty on Russian sanctions
FDA change ushers in cheaper, easier-to-get hearing aids
NASDAQ:GOSS

Gossamer Bio - GOSS Stock Forecast, Price & News

$9.02
+0.77 (+9.33%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.12
$9.05
50-Day Range
$8.25
$12.87
52-Week Range
$5.64
$15.19
Volume
2.48 million shs
Average Volume
1.61 million shs
Market Capitalization
$852.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.30

Gossamer Bio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
125.1% Upside
$20.30 Price Target
Short Interest
Bearish
27.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.27mentions of Gossamer Bio in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$116,270 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.75) to ($2.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

566th out of 1,034 stocks

Pharmaceutical Preparations Industry

267th out of 502 stocks

GOSS stock logo

About Gossamer Bio (NASDAQ:GOSS) Stock

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

GOSS Stock News Headlines

Gossamer Bio (NASDAQ:GOSS) Sees Strong Trading Volume
Gossamer Bio (NASDAQ:GOSS) Stock Price Down 4.6%
4 Analysts Have This to Say About Gossamer Bio
Gossamer Bio
What 5 Analyst Ratings Have To Say About Gossamer Bio
Gossamer Bio, Inc. (GOSS)
Peaking Back In On Gossamer Bio
1GOSS : Where Gossamer Bio Stands With Analysts
What 4 Analyst Ratings Have To Say About Gossamer Bio
Gossamer Bio (GOSS) Investor Presentation - Slideshow
See More Headlines
Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

GOSS Company Calendar

Last Earnings
11/03/2022
Today
12/04/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/02/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GOSS
Fax
N/A
Employees
185
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.30
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+125.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-234,000,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.60 per share

Miscellaneous

Free Float
86,635,000
Market Cap
$852.21 million
Optionable
Not Optionable
Beta
0.80

Key Executives

  • Mr. Faheem Hasnain (Age 64)
    Co-Founder, CEO, Pres & Chairman
    Comp: $895.56k
  • Mr. Bryan GiraudoMr. Bryan Giraudo (Age 47)
    COO & CFO
    Comp: $651.8k
  • Mr. Christian Waage (Age 55)
    Exec. VP of Technical Operations & Admin.
    Comp: $583.16k
  • Dr. Laura L. Carter Ph.D. (Age 55)
    Chief Scientific Officer
  • Mr. Jeff Boerneke
    Gen. Counsel & Sec.
  • Ms. Deanna Weber
    Sr. VP of HR
  • Dr. Richard Aranda M.D. (Age 62)
    Chief Medical Officer
  • Mr. Mario Orlando
    Sr. VP of Commercial New Product Planning
  • Ms. Caryn L. Peterson (Age 63)
    Exec. VP of Regulatory Affairs
  • Mr. Matt Cravets
    Sr. VP of Biometrics













GOSS Stock - Frequently Asked Questions

Should I buy or sell Gossamer Bio stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GOSS shares.
View GOSS analyst ratings
or view top-rated stocks.

What is Gossamer Bio's stock price forecast for 2023?

10 Wall Street analysts have issued 12-month price targets for Gossamer Bio's stock. Their GOSS share price forecasts range from $15.00 to $25.00. On average, they predict the company's stock price to reach $20.30 in the next twelve months. This suggests a possible upside of 125.1% from the stock's current price.
View analysts price targets for GOSS
or view top-rated stocks among Wall Street analysts.

How have GOSS shares performed in 2022?

Gossamer Bio's stock was trading at $11.31 on January 1st, 2022. Since then, GOSS shares have decreased by 20.2% and is now trading at $9.02.
View the best growth stocks for 2022 here
.

When is Gossamer Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our GOSS earnings forecast
.

How were Gossamer Bio's earnings last quarter?

Gossamer Bio, Inc. (NASDAQ:GOSS) issued its earnings results on Thursday, November, 3rd. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.01.

What other stocks do shareholders of Gossamer Bio own?
When did Gossamer Bio IPO?

(GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.

What is Gossamer Bio's stock symbol?

Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."

Who are Gossamer Bio's major shareholders?

Gossamer Bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.78%), BlackRock Inc. (5.83%), EcoR1 Capital LLC (4.40%), State Street Corp (4.00%), Boxer Capital LLC (3.78%) and NEA Management Company LLC (3.67%). Insiders that own company stock include Bryan Giraudo, Caryn Peterson, Faheem Hasnain, Jakob Dupont, Laura Carter, Luisa Salter-Cid, Richard Aranda and Waage Christian.
View institutional ownership trends
.

How do I buy shares of Gossamer Bio?

Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gossamer Bio's stock price today?

One share of GOSS stock can currently be purchased for approximately $9.02.

How much money does Gossamer Bio make?

Gossamer Bio (NASDAQ:GOSS) has a market capitalization of $852.21 million. The company earns $-234,000,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis.

How many employees does Gossamer Bio have?

The company employs 185 workers across the globe.

How can I contact Gossamer Bio?

Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The official website for the company is www.gossamerbio.com. The company can be reached via phone at (858) 684-1300 or via email at ir@gossamerbio.com.

This page (NASDAQ:GOSS) was last updated on 12/4/2022 by MarketBeat.com Staff